High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients

ConclusionsThe overall frequencies of theBRCA germline mutations were 10.2% in breast and 30.7% in ovarian cancer patients. These data shed new light into the prevalence ofBRCA mutations in the Arab women population.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: July 2018Source: Redox Biology, Volume 17Author(s): Dong Hou, Zhaojian Liu, Xiuhua Xu, Qiao Liu, Xiyu Zhang, Beihua Kong, Jian-Jun Wei, Yaoqin Gong, Changshun ShaoAbstractPARP inhibitors have been widely tested in clinical trials, especially for the treatment of breast cancer and ovarian cancer, and were shown to be highly successful. Because PARP primarily functions in sensing and repairing DNA strand breaks, the therapeutic effect of PARP inhibition is generally believed to be attributed to impaired DNA repair. We here report that oxidative stress is also increased by PARP inhibition and mediates the an...
Source: Redox Biology - Category: Biology Source Type: research
Authors: Bedoschi GM, Navarro PA, Oktay KH Abstract Cancer is a worldwide public health problem and is the second leading cause of death in the United States. Early detection of cancer and advancement of treatment modalities contributed to declining mortality rates. Consequently, survival rates increased, leading to a greater interest in maintaining the quality of life after cancer treatment. Adjuvant chemotherapy results in an improvement in both disease-free and overall survival. However, chemotherapy treatment is associated with acute and long- term complications for cancer survivors. A special concern of women ...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
(Salk Institute) Salk scientists studying satellite RNAs discovered that a specific type called hSATa induces breast cancer by directly interfering with DNA copying and damage repair. The research, which appeared in the journal Molecular Cell on June 7, 2018, suggests that targeting satellite RNAs could provide another approach for treating multiple types of cancer, including breast, ovarian, prostate and pancreatic.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Contributors : Dapeng Hao ; Yuan Meng ; Li-Jun DiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDeficiency in homologous recombination repair (HRR) is frequently associated with hormone-responsive cancers. Epithelial ovarian cancer (EOC) is a typical hormone-related tumor, with defects of HRR in up to half of cases. However, whether there are molecular connections between estrogen signaling and HRR deficiency in EOC remains unknown. Here we report an inverse correlation between estrogen signaling and HRR activity in EOC. Genome-wide mapping of ER α reveals ERα co-bindings...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Abstract Choosing the optimal therapy for a patient's cancer has long been based on whether the cancer demonstrates a predictive marker of efficacy. The U.S. Food and Drug Administration (FDA) has now approved use of a targeted therapy based solely on tumor molecular markers (pembrolizumab for tumors with deficient mismatch repair [MMR] and high microsatellite instability [MSI]) and approved another therapy based solely on a germline mutation as the predictive marker of benefit (olaparib for BRCA carriers with ovarian or breast cancer) [New Engl J Med 2017;377:1409-1412, N Engl J Med 2012;366:1382-1392, N Eng J Me...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Publication date: July 2018 Source:Redox Biology, Volume 17 Author(s): Dong Hou, Zhaojian Liu, Xiuhua Xu, Qiao Liu, Xiyu Zhang, Beihua Kong, Jian-Jun Wei, Yaoqin Gong, Changshun Shao PARP inhibitors have been widely tested in clinical trials, especially for the treatment of breast cancer and ovarian cancer, and were shown to be highly successful. Because PARP primarily functions in sensing and repairing DNA strand breaks, the therapeutic effect of PARP inhibition is generally believed to be attributed to impaired DNA repair. We here report that oxidative stress is also increased by PARP inhibition and mediates the antitum...
Source: Redox Biology - Category: Biology Source Type: research
AbstractA challenge in counseling patients with a family history suggesting a hereditary cancer syndrome is deciding which genetic tests or panels to order. In this article, we discuss the identification of multiple familial mutations through genetic counseling and panel testing. For patients meeting National Comprehensive Cancer Network criteria for clinical genetic testing, providers should consider expanded panels to provide a more complete assessment of one's genetic risk. The continued use of expanded panel testing in the clinical setting will help inform optimal management of cancer patients, as well as the managemen...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Precision Medicine, Cancer Diagnostics and Molecular Pathology Precision Medicine Clinic: Molecular Tumor Board Source Type: research
Opinion statementThe single agent activity of PARP inhibitors (PARPi) in germlineBRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progr...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS:  The novel combination of the next generation DNMTi guadecitabine and the first-in-class PARPi talazoparib inhibited breast and ovarian cancers harboring either wildtype- or mutant-BRCA, supporting further clinical exploration of this drug combination in PARPi-resistant cancers. PMID: 29615458 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Middle East Health | Ovarian Cancer | Ovaries | Women